US 11795180
Formulation of a pan-JAK inhibitor
granted A61KA61K31/46A61K45/06
Quick answer
US patent 11795180 (Formulation of a pan-JAK inhibitor) held by Theravance Biopharma R&D IP, LLC expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 24
- CPC classes
- A61K, A61K31/46, A61K45/06, A61K47/02, A61K47/38